TY - JOUR

T1 - Hypothesis

T2 - AA amyloidosis is a factor causing systemic complications after coronavirus disease

AU - Galkin, Alexey P.

N1 - Publisher Copyright: © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021

Y1 - 2021

N2 - The severe course of COVID-19 causes systemic chronic inflammation and thrombosis in a wide variety of organs and tissues. The nature of these inflammations remains a mystery, although they are known to occur against the background of a high level of cytokine production. The high level of cytokines provokes overproduction of the Serum amyloid A (SAA) protein. Moreover, the number of studies has shown that the severe COVID-19 causes SAA overproduction. The authors of these works regard a high level of SAA exclusively as a biomarker of COVID-19. However, it should be borne in mind that overproduction of SAA can cause systemic AA amyloidosis. SAA forms cytotoxic amyloid deposits in various organs and induces inflammation and thrombosis. The consequences of COVID-19 infection are surprisingly similar to the clinical picture that is observed in AA amyloidosis. Here I present the hypothesis that AA amyloidosis is a factor causing systemic complications after coronavirus disease.

AB - The severe course of COVID-19 causes systemic chronic inflammation and thrombosis in a wide variety of organs and tissues. The nature of these inflammations remains a mystery, although they are known to occur against the background of a high level of cytokine production. The high level of cytokines provokes overproduction of the Serum amyloid A (SAA) protein. Moreover, the number of studies has shown that the severe COVID-19 causes SAA overproduction. The authors of these works regard a high level of SAA exclusively as a biomarker of COVID-19. However, it should be borne in mind that overproduction of SAA can cause systemic AA amyloidosis. SAA forms cytotoxic amyloid deposits in various organs and induces inflammation and thrombosis. The consequences of COVID-19 infection are surprisingly similar to the clinical picture that is observed in AA amyloidosis. Here I present the hypothesis that AA amyloidosis is a factor causing systemic complications after coronavirus disease.

KW - AA amyloidosis

KW - chronic inflammation

KW - Coronavirus

KW - COVID-19

KW - serum amyloid A

KW - COVID-19/complications

KW - Humans

KW - Biomarkers

KW - Inflammation

KW - Amyloidosis/blood

KW - Serum Amyloid A Protein

UR - http://www.scopus.com/inward/record.url?scp=85104696292&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/a12f7b5b-cb92-30d1-b447-be5a0e532d1c/

U2 - 10.1080/19336896.2021.1910468

DO - 10.1080/19336896.2021.1910468

M3 - Editorial

C2 - 33876719

AN - SCOPUS:85104696292

VL - 15

SP - 53

EP - 55

JO - Prion

JF - Prion

SN - 1933-6896

IS - 1

ER -